0.02 0.00(0.00%) May 24, 1:58AM EDT
| Prev Close: | 0.02 |
|---|
| Open: | 0.02 |
|---|
| Bid: | 0.02 |
|---|
| Ask: | 0.02 |
|---|
| 1y Target Est: | 0.02 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.02 - 0.02 |
|---|
| 52wk Range: | 0.02 - 0.03 |
|---|
| Volume: | 173,345 |
|---|
| Avg Vol (3m): | 914,278 |
|---|
| Market Cap: | 13.56M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in AUD.
Headlines
- Change of Director's Interest Noticeat Reuters(Sun, May 5)
- North Pratt Coal Mine Progress - April 2013at Reuters(Mon, Apr 22)
- Change of Director's Interest Noticeat Reuters(Sun, Mar 3)
- Ceasing to be a substantial holder - AHZat Reuters(Mon, Feb 11)
- Update on search for ATC marketing partnersat Reuters(Sun, Dec 16)
- Change of Director's Interest Notice - Bruce Hewettat Reuters(Tue, Nov 13)
- Change of Director's Interest Notice - Iain Kirkwoodat Reuters(Tue, Nov 13)
- Chairman on Coal Investmentat Reuters(Tue, Nov 13)
- Avexa to invest US$4M in North American Coal Mine to fund drug developmentat Reuters(Sun, Nov 4)
- Results from testing lead anti-bacterial compound AVX13616at Reuters(Wed, Oct 24)
- CEO on Integrase Developmentsat Reuters(Sun, Sep 30)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 25.21 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Jun-11)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | 5.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Avexa Limited, a biotechnology company, engages in the discovery, development, and commercialization of anti-infective pharmaceutical medicines for the treatment of human infectious diseases.
View More 
0.06%